PrEPared to Choose (PtC) is an Implementation Study of the Delivery of Cabotegravir Long-acting, an Injectable Pre-exposure Prophylaxis (PrEP) Option for HIV Prevention. Injectable PrEP Will be Offered Alongside Oral and Vaginal Ring PrEP From Within a Real-world Context in Cape Town, South Africa.

RecruitingOBSERVATIONAL
Enrollment

1,800

Participants

Timeline

Start Date

February 13, 2024

Primary Completion Date

December 31, 2025

Study Completion Date

March 31, 2026

Conditions
HIV InfectionSexual and Reproductive Health
Interventions
DRUG

Cabotegravir long-acting

3ml intramuscular injection containing 600mg of Cabotegravir

DRUG

Tenofovir emtricitabine

Oral tablet taken daily to PrEP HIV infection.

DRUG

Dapivirine containing vaginal ring

Intra-vaginal silicone ring containing slow-release Dapivirine, replaced every 28 days

Trial Locations (1)

7925

RECRUITING

Desmond Tutu Health Foundation, Cape Town

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Bill and Melinda Gates Foundation

OTHER

collaborator

ViiV Healthcare

INDUSTRY

lead

Desmond Tutu HIV Foundation

OTHER